1. Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19
   Antonio Vitiello et al, 2021, Medical Hypotheses CrossRef
2. Pharmacological agents modifying the renin angiotensin and natriuretic peptide systems in COVID-19 patients
   Antonio Vitiello et al, 2021, Wiener klinische Wochenschrift CrossRef
3. C-Type Natriuretic Peptide (CNP) Inhibition of Interferon-γ-Mediated Gene Expression in Human Endothelial Cells In Vitro
   Amy Day et al, 2018, Biosensors CrossRef
4. C-Type Natriuretic Peptide: A Multifaceted Paracrine Regulator in the Heart and Vasculature
   Amie J. Moyes et al, 2019, International Journal of Molecular Sciences CrossRef
5. C-type natriuretic peptide ameliorates pulmonary fibrosis by acting on lung fibroblasts in mice
   Toru Kimura et al, 2016, Respiratory Research CrossRef
6. The Role of Natriuretic Peptides in the Regulation of Cardiac Tolerance to Ischemia/Reperfusion and Postinfarction Heart Remodeling
   Andrey V. Krylatov et al, 2021, Journal of Cardiovascular Pharmacology and Therapeutics CrossRef
7. Molecular Physiology of Membrane Guanylyl Cyclase Receptors
   Michaela Kuhn, 2016, Physiological Reviews CrossRef
8. Cardiac morphological and functional changes induced by C-type natriuretic peptide are different in normotensive and spontaneously hypertensive rats
   Carolina Caniffi et al, 2020, Journal of Hypertension CrossRef
9. The role of natriuretic peptides in regulation of cardiovascular system
   V. N. Khirmanov, 2017, Kardiologiya i serdechno-sosudistaya khirurgiya CrossRef
10. Chitosan and thiolated chitosan: Novel therapeutic approach for preventing corneal haze after chemical injuries
    Forouhe Zahir-Jouzdani et al, 2018, Carbohydrate Polymers CrossRef
11. C53: A novel particulate guanylyl cyclase B receptor activator that has sustained activity in vivo with anti-fibrotic actions in human cardiac and renal fibroblasts
    Yang Chen et al, 2019, Journal of Molecular and Cellular Cardiology CrossRef